Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Strontium ranelate

Strontium ranelate

pharmaceutical raw materials
Strontium ranelate structure

Strontium ranelate 

structure
  • CAS No:

    135459-87-9

  • Formula:

    C12H10N2O8S.2Sr

  • Chemical Name:

    Strontium ranelate

  • Synonyms:

    3-Thiopheneacetic acid,5-[bis(carboxymethyl)amino]-2-carboxy-4-cyano-,strontium salt (1:2);S 12911;Strontium ranelate;Protos;S 12911-2;Protelos;Distrontium renelate;Bivalos;Osseor;Strometta

  • Categories:

    Organic Chemistry  >  Organometallic Compounds

Description

Strontium ranelate(S12911) stimulates the calcium sensing receptors (CaSR) and leads to the differentiation of pre-osteoblast to osteoblast which increases the bone formation.IC50 value:Target: CaSRStrontium Ranelate is a bone metabolism modulator that inhibits bone resorption while maintaining bone formation. Strontium Ranelate acts by increasing bone formation and decreasing bone resorption, thus rebalancing bone turnover in favour of bone formation, an effect that results in increased

Strontium ranelate Basic Attributes

513.49000

513.79600

391RT5Q293

DTXSID7046918

M05BX03|M - Musculo-skeletal system

2942000000

Characteristics

160.47000

1.8±0.1 g/cm3

>310°C (dec.)

778.8ºC at 760 mmHg

424.8ºC

1.695

H2O: soluble 1mg/mL, clear (warmed)

Safety Information

3077

20/21/22

36/37

XM7581000

Xn

P280

H302 + H312 + H332

|Warning|H302+H312+H332 (95.24%): Harmful if swallowed, in contact with skin or if inhaled [Warning Acute toxicity, oral; acute toxicity, dermal; acute toxicity, inhalation]|P261, P264, P270, P271, P280, P301+P312, P302+P352, P304+P312, P304+P340, P312, P322, P330, P363, and P501|Aggregated GHS information provided by 42 companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.|H362 (100%): May cause harm to breast-fed children [Reproductive toxicity, effects on or via lactation]|P201, P260, P263, P264, P270, and P308+P313|Aggregated GHS information provided by 52 companies from 1 notifications to the ECHA C&L Inventory.

Drug Information

Treatment of severe osteoporosis in postmenopausal women at high risk for fracture to reduce the risk of vertebral and hip fractures., , Treatment of severe osteoporosis in adult men at increased risk of fracture., , The decision to prescribe strontium ranelate should be based on an assessment of the individual patient's overall risks.,|Treatment of osteoporosis|Osteoporosis

Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)

3-(3-cyano-4-carboxymethyl-5-carboxy-2-thienyl)-3-azapentanedioic distrontium salt

Strontium ranelate Use and Manufacturing

Uses

Bone metabolism modulator; inhibits bone resorption while maintaining bone formation. Antiosteoporotic

Human drugs -> Osseor -> EMA Drug Category|Drugs for treatment of bone diseases -> Human pharmacotherapeutic group|Human drugs -> Protelos -> EMA Drug Category|Human Drugs -> EU pediatric investigation plans

Computed Properties

Molecular Weight:639.6
Hydrogen Bond Donor Count:7
Hydrogen Bond Acceptor Count:18
Rotatable Bond Count:4
Exact Mass:639.8696636
Monoisotopic Mass:639.8696636
Topological Polar Surface Area:223
Heavy Atom Count:32
Complexity:533
Covalently-Bonded Unit Count:10
Compound Is Canonicalized:Yes

Drug Function and Efficacy

No specific description provided

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Recommended Suppliers of Strontium ranelate

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.